Twenty-four parkinsonian patients compared pergolide and bromocriptine therapy in a randomized double-blind, two-period crossover study. Both drugs were adjusted to an optimal balance between benefits and side effects. The mean daily dose and dose range for pergolide and bromocriptine were 3.3 mg (0.7 to 7.2) and 42.7 mg (5.8 to 87.5), respectively. Adjunctive medications, which for most patients included levodopa (plus carbidopa), were not altered during the study. A similar spectrum of clinical effects was found with both drugs and with lisuride, which was used to treat 13 of the patients in a previous study. Despite neurochemical differences in the antiparkinsonian ergots, their clinical utility is quite similar. We draw attention to hepatotoxicity and pleural reactions that may occur rarely with these drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/wnl.33.8.1009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dopamine agonists versus levodopa monotherapy in early Parkinson's disease for the potential risks of motor complications: A network meta-analysis.
Eur J Pharmacol
September 2023
Department of Neurology, Bishan Hospital of Chongqing Medical University, Chongqing, 402760, China. Electronic address:
Article Synopsis
- In early Parkinson's disease, dopamine agonists (DAs) tend to have lower motor complications compared to levodopa, but there's no clear evidence showing one DA is more effective than another in this regard.
- A network meta-analysis was conducted involving nine randomized controlled trials (RCTs) with over 2,100 patients to compare levodopa and four DAs: pramipexole, ropinirole, bromocriptine, and pergolide for their impact on motor complications.
- Results indicated that while levodopa was associated with the highest risk of dyskinesia, pramipexole had the lowest risk of wearing-off effects, suggesting the need for further research on these treatments.
Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature.
J Med Case Rep
March 2023
Ministry of Health Holdings, 1 Maritime Square, #11-25 HarbourFront Centre, Singapore, 099253, Singapore.
Background: Resistance to dopamine agonists is not uncommonly seen in prolactinomas. However, development of resistance to dopamine agonists after an initial period of robust treatment response is rare, and only 39 cases have been reported in the past four decades. We describe a Chinese man with this rare condition and explored the postulated mechanisms that may explain this phenomenon.
View Article and Find Full Text PDFThe Inhibitory Effect of Selected D Dopaminergic Receptor Agonists on VEGF-Dependent Neovascularization in Zebrafish Larvae: Potential New Therapy in Ophthalmic Diseases.
Cells
April 2022
Oftalabs Sp. z o.o., Wrocławska 130, 58-306 Wałbrzych, Poland.
Pathological angiogenesis is correlated with many ophthalmic diseases. The most common are exudative age-related macular degeneration and proliferative diabetic retinopathy. The current treatment for these diseases is based on regularly administered anti-VEGF antibodies injections.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!